# Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects

> **NCT00434577** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 715 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Herpes Zoster vaccine GSK1437173A Low Dose
- **BIOLOGICAL:** Herpes Zoster vaccine GSK1437173A Medium Dose
- **BIOLOGICAL:** Herpes Zoster vaccine GSK1437173A High Dose
- **BIOLOGICAL:** Herpes Zoster vaccine GSK1437173A Modified
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00434577
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-14
- **Primary completion:** 2007-10-04
- **Final completion:** 2010-07-14
- **Target enrollment:** 715 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434577, "Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00434577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*